Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000020.xml
Geburtshilfe Frauenheilkd 2023; 83(11): 1319-1326
DOI: 10.1055/a-2162-5964
DOI: 10.1055/a-2162-5964
GebFra Magazin
Aktuell diskutiert
Migräne: Kinderwunsch, Schwangerschaft, Stillzeit
Migräne ist insbesondere bei Frauen eine häufige Erkrankung. Die höchste Prävalenz besteht in der fruchtbaren Lebensphase der Frau. Auch wenn sich die Migräne in der Schwangerschaft oft bessert, sind Empfehlungen für die medikamentöse Prophylaxe und Behandlung der Migräne bedeutsam. Dieser Beitrag liefert einen Überblick zu Migränemedikamenten – insbesondere mit Blick auf ihre Anwendung bei der schwangeren Patientin.
Publication History
Article published online:
03 November 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Fox AW, Diamond ML, Spierings EL. Migraine during pregnancy: options for therapy. CNS Drugs 2005; 19: 465-481 DOI: 10.2165/00023210-200519060-00001.
- 2 Allais G, Chiarle G, Sinigaglia S. et al. Migraine during pregnancy and in the puerperium. Neurol Sci 2019; 40: 81-91 DOI: 10.1007/s10072-019-03792-9.
- 3 Skajaa N, Szépligeti SK, Xue F. et al. Pregnancy, Birth, Neonatal, and Postnatal Neurological Outcomes After Pregnancy With Migraine. Headache 2019; 59: 869-879 DOI: 10.1111/head.13536.
- 4 Ishii R, Schwedt TJ, Kim SK. et al. Effect of Migraine on Pregnancy Planning: Insights From the American Registry for Migraine Research. Mayo Clin Proc 2020; 95: 2079-2089 DOI: 10.1016/j.mayocp.2020.06.053.
- 5 Marxer CA, Rüegg S, Rauch MS. et al. A review of the evidence on the risk of congenital malformations and neurodevelopmental disorders in association with antiseizure medications during pregnancy. Expert Opin Drug Saf 2021; 20: 1487-1499 DOI: 10.1080/14740338.2021.1943355.
- 6 Reynolds EH, Green R. Valproate and folate: Congenital and developmental risks. Epilepsy Behav 2020; 108: 107068 DOI: 10.1016/j.yebeh.2020.107068.
- 7 Wlodarczyk BJ, Palacios AM, George TM. et al. Antiepileptic drugs and pregnancy outcomes. Am J Med Genet A 2012; 158a: 2071-2090 DOI: 10.1002/ajmg.a.35438.
- 8 Källén B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf 2011; 34: 691-703 DOI: 10.2165/11590370-000000000-00000.
- 9 Marchenko A, Etwel F, Olutunfese O. et al. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache 2015; 55: 490-501 DOI: 10.1111/head.12500.
- 10 Spielmann K, Kayser A, Beck E. et al. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2018; 38: 1081-1092 DOI: 10.1177/0333102417724152.
- 11 Noseda R, Bedussi F, Gobbi C. et al. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database. Cephalalgia 2021; 41: 789-798 DOI: 10.1177/0333102420983292.
- 12 Cheng F, Ahmed F. OnabotulinumtoxinA for the prophylactic treatment of headaches in adult patients with chronic migraine: a safety evaluation. Expert Opin Drug Saf 2021; 20: 1275-1289 DOI: 10.1080/14740338.2021.1948531.
- 13 Amundsen S, Nordeng H, Nezvalová-Henriksen K. et al. Pharmacological treatment of migraine during pregnancy and breastfeeding. Nat Rev Neurol 2015; 11: 209-219 DOI: 10.1038/nrneurol.2015.29.
- 14 OʼQuinn S, Ephross SA, Williams V. et al. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch Gynecol Obstet 1999; 263: 7-12 DOI: 10.1007/s004040050252.
- 15 Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 2003; 17: 1-7 DOI: 10.2165/00023210-200317010-00001.
- 16 Fiore M, Shields KE, Santanello N. et al. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia 2005; 25: 685-688 DOI: 10.1111/j.1468-2982.2004.00929.x.
- 17 Evans EW, Lorber KC. Use of 5-HT1 agonists in pregnancy. Ann Pharmacother 2008; 42: 543-549 DOI: 10.1345/aph.1K176.
- 18 Diener HC, Gaul C, Kropp P. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie, 2018. In: DGN, Hrsg. Leitlinien für Diagnostik und Therapie in der Neurologie. Accessed May 05, 2023 at: http://www.dgn.org/leitlinien
- 19 Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie. Accessed May 05, 2023 at: http://www.embryotox.de/
- 20 Sances G, Granella F, Nappi RE. et al. Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23: 197-205 DOI: 10.1046/j.1468-2982.2003.00480.x.
- 21 Kvisvik EV, Stovner LJ, Helde G. et al. Headache and migraine during pregnancy and puerperium: the MIGRA-study. J Headache Pain 2011; 12: 443-451 DOI: 10.1007/s10194-011-0329-1.
- 22 Tepper D. Pregnancy and lactation – migraine management. Headache 2015; 55: 607-608 DOI: 10.1111/head.12540.
- 23 Govindappagari S, Grossman TB, Dayal AK. et al. Peripheral nerve blocks in the treatment of migraine in pregnancy. Obstet Gynecol 2014; 124: 1169-1174 DOI: 10.1097/aog.0000000000000555.
- 24 Robinson AY, Grogan PM. OnabotulinumtoxinA successfully used as migraine prophylaxis during pregnancy: a case report. Mil Med 2014; 179: e703-e704 DOI: 10.7205/milmed-d-13-00477.